[
    [
        {
            "time": "2021-04-01",
            "original_text": "医药生物行业：为什么说智飞生物二季度有望迎来亮眼表现？",
            "features": {
                "keywords": [
                    "智飞生物",
                    "二季度",
                    "亮眼表现"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药生物行业：为什么说智飞生物二季度有望迎来亮眼表现？",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-04-01",
            "original_text": "医药行业2021年4月投资月报：把握一季报最佳反弹窗口期 加配低估值且高增长标的",
            "features": {
                "keywords": [
                    "医药行业",
                    "一季报",
                    "反弹窗口期",
                    "低估值",
                    "高增长"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业2021年4月投资月报：把握一季报最佳反弹窗口期 加配低估值且高增长标的",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        },
        {
            "time": "2021-04-01",
            "original_text": "医药行业周报：当前是反弹最佳窗口期 加配低估值高增长标的",
            "features": {
                "keywords": [
                    "医药行业",
                    "反弹窗口期",
                    "低估值",
                    "高增长"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业周报：当前是反弹最佳窗口期 加配低估值高增长标的",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        },
        {
            "time": "2021-04-01",
            "original_text": "医药行业每周医览药闻：从2020年财报看国内创新药行业发展",
            "features": {
                "keywords": [
                    "医药行业",
                    "2020年财报",
                    "创新药",
                    "发展"
                ],
                "sentiment_score": 0.65,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药行业每周医览药闻：从2020年财报看国内创新药行业发展",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 3
            }
        },
        {
            "time": "2021-04-01",
            "original_text": "东吴证券--医药生物行业：为何近期医疗服务、医美大幅上涨？【行业研究】",
            "features": {
                "keywords": [
                    "东吴证券",
                    "医药生物",
                    "医疗服务",
                    "医美",
                    "上涨"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "医疗服务",
                    "医美"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "东吴证券--医药生物行业：为何近期医疗服务、医美大幅上涨？【行业研究】",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 5
            }
        },
        {
            "time": "2021-04-01",
            "original_text": "固定收益月报：进入业绩驱动",
            "features": {
                "keywords": [
                    "固定收益",
                    "业绩驱动"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "固定收益月报：进入业绩驱动",
                "Correlation": 2,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 1,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 5,
                "Source_Recency": 5
            }
        },
        {
            "time": "2021-04-01",
            "original_text": "2021年医药行业4月策略报告：Q1业绩高成长是股价核心催化剂",
            "features": {
                "keywords": [
                    "医药行业",
                    "Q1业绩",
                    "高成长",
                    "股价",
                    "催化剂"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "2021年医药行业4月策略报告：Q1业绩高成长是股价核心催化剂",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        }
    ]
]